EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412)
Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 123-124
10.1002/hon.83_2629